Denali Therapeutics reported $17.8 million in net product revenue for Q3 2026 from AVLAYAH, its FDA-approved treatment for Hunter syndrome, with Q4 revenue guidance of $30-32 million. The company also advanced its pipeline, including zafinofusp alfa for Sanfilippo syndrome type A with a planned 2027 BLA submission, and multiple other programs targeting neurological diseases. Q3 net income was $70.1 million, boosted by a $194 million gain from selling a Priority Review Voucher. Denali's cash position remains strong at $1 billion, supporting ongoing research and commercial expansion.
Denali Therapeutics shares rose 6.04% to USD 20.00 on Pluang, reflecting strong investor interest following its Q3 financial results and pipeline updates. The stock trades with a market cap of $3.01 billion and a 52-week range between $14.41 and $27.21. These figures are current as of Nov 04, 2026 04:12 WIB.
